GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Receivables Turnover

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Receivables Turnover : 13.96 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue for the six months ended in Dec. 2023 was HK$0.33 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s average Accounts Receivable for the six months ended in Dec. 2023 was HK$0.02 Mil. Hence, ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover for the six months ended in Dec. 2023 was 13.96.

ImmuneOnco Biopharmaceuticals (Shanghai) Receivables Turnover Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Receivables Turnover Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23
Receivables Turnover
147.71 10.36 7.21

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Receivables Turnover - 11.86 1.70 2.41 13.96

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover falls into.


ImmuneOnco Biopharmaceuticals (Shanghai) Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Receivables Turnover (A: Dec. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2023 ) / ((Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count )
=0.422 / ((0.074 + 0.043) / 2 )
=0.422 / 0.0585
=7.21

ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

Receivables Turnover (Q: Dec. 2023 )
=Revenue / Average Total Inventories
=Revenue (Q: Dec. 2023 ) / ((Accounts Receivable (Q: Jun. 2023 ) + Accounts Receivable (Q: Dec. 2023 )) / count )
=0.328 / ((0.004 + 0.043) / 2 )
=0.328 / 0.0235
=13.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai)  (HKSE:01541) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

ImmuneOnco Biopharmaceuticals (Shanghai) Receivables Turnover Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Receivables Turnover
Comparable Companies
HKSE:09966 HKSE:06660 HKSE:09969 HKSE:01952 HKSE:02105 HKSE:02315 HKSE:06955 HKSE:06855 HKSE:02696 HKSE:06826 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Executives
Gba Fund Investment Limited 2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Halo Biomedical Lp 2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited 2101 Beneficial owner
Halo Biomedical Investment I Limited 2201 Interest of corporation controlled by you
Tian Wenzhi 2501 Other
Lav Immon Hong Kong Limited 2101 Beneficial owner
Greater Bay Area Homeland Investments Limited 2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited 2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited 2101 Beneficial owner
Lav Gp V, L.p. 2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p. 2201 Interest of corporation controlled by you
Shi Yi 2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines